TY - JOUR
T1 - Advances in Radionuclide Therapies for Patients with Neuro-endocrine Tumors
AU - Hoogenkamp, Denise S.
AU - de Wit–van der Veen, Linda J.
AU - Huizing, Daphne M.V.
AU - Tesselaar, Margot E.T.
AU - van Leeuwaarde, Rachel S.
AU - Stokkel, Marcel P.M.
AU - Lam, Marnix G.E.H.
AU - Braat, Arthur J.A.T.
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/5
Y1 - 2024/5
N2 - Purpose of Review: To provide insights into the role of peptide receptor radionuclide therapy (PRRT) in patients with advanced neuroendocrine tumors (NET) and an overview of possible strategies to combine PRRT with locoregional and systemic anticancer treatments. Recent Findings: Research on combining PRRT with other treatments encompasses a wide variety or treatments, both local (transarterial radioembolization) and systemic therapies, chemotherapy (i.e., capecitabine and temozolomide), targeted therapies (i.e., olaparib, everolimus, and sunitinib), and immunotherapies (e.g., nivolumab and pembrolizumab). Furthermore, PRRT shows promising first results as a treatment prior to surgery. Summary: There is great demand to enhance the efficacy of PRRT through combination with other anticancer treatments. While research in this area is currently limited, the field is rapidly evolving with numerous ongoing clinical trials aiming to address this need and explore novel therapeutic combinations.
AB - Purpose of Review: To provide insights into the role of peptide receptor radionuclide therapy (PRRT) in patients with advanced neuroendocrine tumors (NET) and an overview of possible strategies to combine PRRT with locoregional and systemic anticancer treatments. Recent Findings: Research on combining PRRT with other treatments encompasses a wide variety or treatments, both local (transarterial radioembolization) and systemic therapies, chemotherapy (i.e., capecitabine and temozolomide), targeted therapies (i.e., olaparib, everolimus, and sunitinib), and immunotherapies (e.g., nivolumab and pembrolizumab). Furthermore, PRRT shows promising first results as a treatment prior to surgery. Summary: There is great demand to enhance the efficacy of PRRT through combination with other anticancer treatments. While research in this area is currently limited, the field is rapidly evolving with numerous ongoing clinical trials aiming to address this need and explore novel therapeutic combinations.
KW - Combination therapy
KW - Neuroendocrine tumor
KW - Peptide receptor radionuclide therapy
KW - Radioembolization
UR - http://www.scopus.com/inward/record.url?scp=85189886747&partnerID=8YFLogxK
U2 - 10.1007/s11912-024-01521-w
DO - 10.1007/s11912-024-01521-w
M3 - Review article
C2 - 38598035
AN - SCOPUS:85189886747
SN - 1523-3790
VL - 26
SP - 551
EP - 561
JO - Current Oncology Reports
JF - Current Oncology Reports
IS - 5
ER -